APA (7th ed.) Citation

SC, M., XR, T., LL, L., X, B., JG, Z., ZJ, D., . . . ZY, D. (2021). Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: Results from two randomized studies. Oncoimmunology, 10(1), 1909296. https://doi.org/10.1080/2162402X.2021.1909296

Chicago Style (17th ed.) Citation

SC, Ma, et al. "Integrative Evaluation of Primary and Metastatic Lesion Spectrum to Guide Anti-PD-L1 Therapy of Non-small Cell Lung Cancer: Results from Two Randomized Studies." Oncoimmunology 10, no. 1 (2021): 1909296. https://doi.org/10.1080/2162402X.2021.1909296.

MLA (9th ed.) Citation

SC, Ma, et al. "Integrative Evaluation of Primary and Metastatic Lesion Spectrum to Guide Anti-PD-L1 Therapy of Non-small Cell Lung Cancer: Results from Two Randomized Studies." Oncoimmunology, vol. 10, no. 1, 2021, p. 1909296, https://doi.org/10.1080/2162402X.2021.1909296.